CClinicalTrials.gg
Status unknownNCT03323138PACGUpdated Oct 26, 2017

Study on Ex-PRESS Implantation Combined With Phacoemulsification in Primary Angle-closure Glaucoma

An interventional study of Ex-PRESS and phacoemulsification in Glaucoma, Angle-Closure, sponsored by Wenzhou Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by Wenzhou Medical University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Primary angle-closure glaucoma (PACG) is common, phacotrabeculectomy is associated with a significant risk of complications.The Ex-PRESS shunt was introduced as a modification to trabeculectomy, with the theoretical advantages of reduced complications.Our purpose is to perform a prospective study to evaluate the clinical outcomes and safety of the Ex-PRESS shunt with cataract surgery for PACG patients coexisting cataract.

Read the detailed description

The Ex-PRESS is a miniature stainless steel glaucoma device, developed as an alternative to trabeculectomy mainly for patients with primary open-angle glaucoma.It has been proved to be as effective as trabeculectomy in a series of researches. However the early postoperative complication of Ex-PRESS implantation is less frequent compared with trabeculectomy. Ex-PRESS was designed initially for open angle glaucoma, gradually some scholars used it in refractory postpenetrating keratoplasty glaucoma and in vitrectomized glaucoma,which showed that Ex-PRESS shunt implantation was an effective procedure too. We analyzed the clinical efficacy and safety of combined phacoemulsification and Ex-PRESS implantation for PACG patients with cataract. Data was recorded before surgery and postoperatively at 1 week and 1, 3, 6, 12,18,24,30,36 months,which included intraocular pressure (IOP), best corrected visual acuity (BCVA), number of medications, complications, corneal endothelial cell density and anterior segment optical coherence tomography(AS-OCT). Efficacy was assessed by IOP values and success rates. Complete success was determined by IOP between 5 and 21mmHg without medications.

02

Conditions studied

  • Glaucoma, Angle-Closure

Keywords

  • Ex-PRESS
  • glaucoma
  • filtration surgery
  • phacoemulsification
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The presence of PACG, angle peripheral anterior synechia (PAS) more than 180 degrees.
  • An indication for glaucoma filtering surgery based on uncontrolled IOP or progressive vision field defect despite antiglaucoma medications.
  • Mean vision field defect greater than 15dB.
  • The presence of a clinically significant decrease of visual acuity as a result of cataract, usually BCVA less than 0.6.

Exclusion criteria

Exclusion Criteria:

  • Patients unable to give informed consent.
  • Ocular infection or inflammation in the study eye in the 3 months prior to enrollment.
  • Intraocular surgery in the study eye in the 3 months prior to enrollment.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ex-PRESS and phacoemulsification

    A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).

    Procedure: Ex-PRESS and phacoemulsification

Interventions

  • ProcedureEx-PRESS and phacoemulsification
05

What researchers measure

Primary outcomes

  1. Intraocular pressure (IOP)

    In millimeters of mercury (mmHg), measured with the Goldmann applanation tonometer

    Time frame: 36 months

Secondary outcomes

  1. Intraocular pressure (IOP)

    In millimeters of mercury (mmHg), measured with the Goldmann applanation tonometer

    Time frame: 2 weeks, 1 month, 3 months, 6 months, 12 months,18 months, 24 months, 30 months,36 months.

  2. Number of intraocular pressure lowering medications

    Number of drops and oral medications used by the patient compared to baseline

    Time frame: 2 weeks, 1 month, 3 months, 6 months, 12 months,18 months, 24 months, 30 months,36 months.

  3. Best corrected visual acuity (BCVA)

    Number of lines reduction or improvement from baseline on Snellen acuity chart

    Time frame: 2 weeks, 1 month, 3 months, 6 months, 12 months,18 months, 24 months, 30 months,36 months.

  4. Corneal endothelial cell density

    Use non-contact specular microscope to count the endothelial cell density (cells/mm2)

    Time frame: 3 months

  5. Anterior chamber distance(ACD)

    The distance from inner corneal surface to lens measured by AS-OCT

    Time frame: 3 months

  6. Angle opening distance(AOD500)

    Angle opening distance 500um from the scleral spur measured by AS-OCT

    Time frame: 3 months

06

Study locations

1 of 1 sites recruiting
  • Ophthalmology and Optometry Hospital , Wenzhou Medical University
    Wenzhou, Zhejiang 325027, China
    Recruiting
07

References and documents

Publications

  • Lai JS, Tham CC, Lam DS. Incisional surgery for angle closure glaucoma. Semin Ophthalmol. 2002 Jun;17(2):92-9. doi: 10.1076/soph.17.2.92.14716. PubMed 15513462 ↗
  • Tham CC, Lai JS, Poon AS, Lai TY, Lam DS. Results of trabeculectomy with adjunctive intraoperative mitomycin C in Chinese patients with glaucoma. Ophthalmic Surg Lasers Imaging. 2006 Jan-Feb;37(1):33-41. PubMed 16468549 ↗
  • Tham CC, Kwong YY, Leung DY, Lam SW, Li FC, Chiu TY, Chan JC, Lam DS, Lai JS. Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. Ophthalmology. 2009 Apr;116(4):725-31, 731.e1-3. doi: 10.1016/j.ophtha.2008.12.054. Epub 2009 Feb 25. PubMed 19243831 ↗
  • Beltran-Agullo L, Trope GE, Jin Y, Wagschal LD, Jinapriya D, Buys YM. Comparison of visual recovery following ex-PRESS versus trabeculectomy: results of a prospective randomized controlled trial. J Glaucoma. 2015 Mar;24(3):181-6. doi: 10.1097/IJG.0b013e31829e1b68. PubMed 23807352 ↗
  • Gonzalez-Rodriguez JM, Trope GE, Drori-Wagschal L, Jinapriya D, Buys YM. Comparison of trabeculectomy versus Ex-PRESS: 3-year follow-up. Br J Ophthalmol. 2016 Sep;100(9):1269-73. doi: 10.1136/bjophthalmol-2015-307161. Epub 2015 Dec 16. PubMed 26674779 ↗
  • Netland PA, Sarkisian SR Jr, Moster MR, Ahmed II, Condon G, Salim S, Sherwood MB, Siegfried CJ. Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). Am J Ophthalmol. 2014 Feb;157(2):433-440.e3. doi: 10.1016/j.ajo.2013.09.014. Epub 2013 Nov 7. PubMed 24210765 ↗
  • Zhang M, Li B, Sun Y. EX-PRESS and ahmed glaucoma valve in treatment of refractory glaucoma. Acta Ophthalmol. 2016 Aug;94(5):e382-3. doi: 10.1111/aos.12898. Epub 2015 Dec 8. No abstract available. PubMed 26643962 ↗
  • Liu B, Guo DD, Du XJ, Cong CY, Ma XH. Evaluation of Ex-PRESS implantation combined with phacoemulsification in primary angle-closure glaucoma. Medicine (Baltimore). 2016 Sep;95(36):e4613. doi: 10.1097/MD.0000000000004613. PubMed 27603352 ↗
  • Wagschal LD, Trope GE, Jinapriya D, Jin YP, Buys YM. Prospective Randomized Study Comparing Ex-PRESS to Trabeculectomy: 1-Year Results. J Glaucoma. 2015 Oct-Nov;24(8):624-9. doi: 10.1097/IJG.0000000000000029. PubMed 24247999 ↗
  • Marzette L, Herndon LW. A comparison of the Ex-PRESS mini glaucoma shunt with standard trabeculectomy in the surgical treatment of glaucoma. Ophthalmic Surg Lasers Imaging. 2011 Nov-Dec;42(6):453-9. doi: 10.3928/15428877-20111017-03. PubMed 22074705 ↗
  • Vetrugno M, Ferreri P, Sborgia C. Ex-PRESS miniature glaucoma device in vitrectomized eyes. Eur J Ophthalmol. 2010 Sep-Oct;20(5):945-7. doi: 10.1177/112067211002000521. PubMed 20306441 ↗
  • Kanner EM, Netland PA, Sarkisian SR Jr, Du H. Ex-PRESS miniature glaucoma device implanted under a scleral flap alone or combined with phacoemulsification cataract surgery. J Glaucoma. 2009 Aug;18(6):488-91. doi: 10.1097/IJG.0b013e31818fb44e. PubMed 19223790 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03323138
Lead sponsor
Wenzhou Medical University
Responsible party
yin ying zhao (MD, Wenzhou Medical University) — Principal investigator
First posted
Oct 26, 2017
Start date
Jul 1, 2012
Primary completion
Jan 2018 (estimated)
Completion
Dec 30, 2018 (estimated)
Last update
Oct 26, 2017

Study contacts

Li Nie, MD
Contact
hehemao2003@163.com
+86-0571-86795965
Ai wu Fang, MD
Contact
953736995@qq.com
+86-0571-88068888
Ai wu Fang, MD
principal investigator · Wenzhou Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion